Skip to content

Study · Non-randomized trial · n = 635 · 2018

3 results

[Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children].

Zykov VP, Serebrennikova EB, Panchenko TN, Sycheva YB, Presnyakova SN, Mazur EL, Salova MN, Golubeva ES, Khromova SK

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2018Cited by 10 (Europe PMC)

PMID29652302 (opens in a new tab)DOI10.17116/jnevro20181183127-31 (opens in a new tab)PepBankPUB-29652302
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with cognitive dysfunction, Cortexin treatment produced a reported effect on cognitive impairment without a quantified magnitude.

    In plain wordsIn children with cognitive dysfunction, the study reported a cognitive benefit after Cortexin treatment without its size.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseCognitive function
    Study

    n = 635

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The reliable effect of cortexin on cognitive impairment was shown.
    2 context sentences
    Summary · context
    The study included 635 patients, aged 3-7 years.
    Summary · context
    Standard treatment of cortexin, including 10 intramuscular injections, was used.
  2. 02HumanNon-randomized trialSafety outcome

    In children with cognitive dysfunction, Cortexin had reported good tolerability without event counts.

    In plain wordsIn children with cognitive dysfunction, the study reported good Cortexin tolerability without event counts.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedTolerability
    Study

    n = 635

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The tolerability of cortexin was good.
    2 context sentences
    Summary · context
    The study included 635 patients, aged 3-7 years.
    Summary · context
    Standard treatment of cortexin, including 10 intramuscular injections, was used.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children, those with ADHD aged 3-4 years showed the best Cortexin response, particularly on thinking tests.

    In plain wordsIn children, those with ADHD aged 3-4 years showed the best response to Cortexin among the studied groups, particularly on thinking tests.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseThinking test response in young children with ADHD
    Study

    n: not reported in source

    Comparator
    Other clinical and age groups
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The best response to treatment was observed in patients with ADHD, aged 3-4 years, in particular on the tests measuring thinking.
    2 context sentences
    Summary · context
    The study included 635 patients, aged 3-7 years.
    Summary · context
    Standard treatment of cortexin, including 10 intramuscular injections, was used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.